Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Citi
Johnson and Johnson
Express Scripts
QuintilesIMS

Generated: August 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,127,266

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,127,266
Title:Asparaginase enzyme variants and uses thereof
Abstract: The present invention relates to newly identified asparaginase polypeptide variants of SEQ ID NO: 3 and to polynucleotide sequences that encode such novel asparaginase variants. Furthermore the invention relates to the use of these novel asparaginase variants in industrial processes.
Inventor(s): Van Der Laan; Jan Metske (Echt, NL), Stor; Mark Cristiaan (Echt, NL), De Lange; Ilse (Echt, NL), Mohrmann; Lisette (Echt, NL)
Assignee: DSM IP ASSETS B.V. (Heerlen, NL)
Application Number:14/075,711
Patent Claims:1. A variant of a parent polypeptide having asparaginase activity, wherein the variant has an amino acid sequence which, when aligned with the sequence set out in SEQ ID NO: 3, comprises an amino residue corresponding to any of amino acids Tyr or Leu at position 53; Ala, Asn, Asp or Pro at position 64; Asn, Lys or Pro at position 66; Ala or Ser at position 70; Ala, Ser, Asn or Glu at position 71; His, Ser, Asn, Asp, Gln, Glu, Arg or Lys at position 73; Ala or Val at position 74; Tyr, Pro or Glu at position 88; Val, Tyr or Phe at position 90; Ser, Asn or Glu at position 91; Ser, Arg or Lys at position 102; Leu, Ile, Phe, Met or Thr at position 103; Ser, Asn or Glu at position 107; Arg, Asp, Gly, Asn or Ser at position 109; Gly, Ser, Thr or H is at position 111; Val, Leu, Phe or Met at position 161; Gly or Ser at position 164; Ala, Gly or Thr at position 168; Ser, Val, Met, Ile, Asn or Gln at position 211; Ser or His at position 214; Ser or Thr at position 215; Ser, Thr, Val, Leu or Phe at position 216; Ala, Ser, Asn, Gln or Glu at position 219; Ala or Ser at position 220; Ala, Ser, Asn or His at position 228; Gly, Ser, Asp, or Ile at position 235; Cys or His at position 262; Tyr at position 267; Asn or Glu at position 271; Asn or Ser at position 295; Gln, Asn, His, Trp Val, Ile or Tyr at position 302; Gly, Leu, Lys, Glu Asp, Ile, Ala, Tyr, Phe or Ser at position 303; Ala, Val, Met or Thr at position 310; Gly, Ala, Ser, Asn, Asp, Gln or His at position 314; Ile at position 317; Ala, Thr, Leu, Arg, Val, Ile, Tyr or His at position 319; Ser, Thr, His, Arg, Lys or Ala at position 321; Ile, Val or Ser at position 323; Met, Ala, Gly or Pro at position 324; Ala, Ser, Thr, Asp, Glu or Trp at position 325; Met, Ile, Pro, Tyr, Ser, Ala, Arg, Val or Thr at position 327; Ser, Thr or Ile at position 328; Ala, Thr, Leu or Gly at position 329; Asp, Glu, Arg, Gln, Val, Pro, Ser, Tyr, Thr, or Ile at position 330; Ala, Thr, Gly, Asn, Asp, Glu, Lys or Arg at position 331; Ala, Asn, Ser, Gly, Glu, Lys, Pro or Gln at position 332; Glu, Asp, Ser, Ile, Phe, Ala, Gly or Lys at position 333; Gly, Thr, Asp, Glu, Pro, Val or Ile at position 334; and Thr, Gly or Asp at position 335, said positions being defined with reference to SEQ ID NO: 3 and wherein the parent polypeptide has at least 90% homology with SEQ ID NO: 3.

2. The variant of claim 1, comprising Tyr at position 53; Pro at position 64; Pro at position 66; Lys at position 73; Ala at position 74; Tyr or Pro at position 88; Val at position 90; Glu at position 91; Gly at position 111; Leu at position 161; Ser at position 211; His at position 228; Cys or His at position 262; Tyr at position 267; Ser at position 295; Ser at position 303; Val at position 310; Asp at position 314; Ile at position 317; Thr at position 321; Gly at position 324; Ser at position 330; Ala at position 332; or Glu at position 333, said positions being defined with reference to SEQ ID NO: 3.

3. The variant of claim 1, comprising Pro at position 66, said position being defined with reference to SEQ ID NO: 3.

4. The variant according to claim 1 which has at least 95% homology with SEQ ID NO: 3.

5. The variant according to claim 1 which has a specific activity, which is higher than that of the parent polypeptide measured at the same pH.

6. The variant according to claim 1, wherein the variant has a pH optimum which is higher than that of the parent polypeptide.

7. The variant according to claim 1 which further comprises additional substitution of amino acid residues selected from an amino residue corresponding to any of amino acids 41, 62, 63, 76, 77, 101, 104, 106, 108, 119, 122, 123, 132, 140, 142, 143, 145, 162, 163, 169, 170, 195, 213, 217, 218, 232, 233, 234, 268, 269, 270, 272, 273, 293, 297, 298, 300, 301, 304, or 371, said positions being defined with reference to SEQ ID NO:3.

8. The variant according to claim 7 which comprises from 1 to 5 additional substitutions.

9. An isolated nucleic acid encoding the variant according to claim 1.

10. A nucleic acid construct comprising the nucleic acid sequence of claim 9 operably linked to one or more control sequences capable of directing the expression of an asparaginase in a suitable expression host.

11. A recombinant expression vector comprising the nucleic acid construct of claim 10.

12. A recombinant host cell comprising the expression vector of claim 11.

13. A method for producing an asparaginase comprising cultivating the host cell of claim 12 under conditions conducive to production of the asparaginase and recovering the asparaginase.

14. A method of producing an asparaginase polypeptide variant according to claim 1, which method comprises: a) selecting a parent asparaginase polypeptide; b) substituting at least one amino acid residue corresponding to any positions 53, 64, 66, 70, 71, 73, 74, 88, 90, 91, 102, 103, 107, 109, 111, 161, 164, 168, 211, 214, 215, 216, 219, 220, 228, 235, 262, 267, 271, 295, 302, 303, 310, 314, 317, 319, 319, 321, 323, 324, 325, 327, 328, 329, 330, 331, 332, 333, 334, or 335, said positions being defined with reference to SEQ ID NO: 3, and wherein the parent polypeptide has at least 90% homology with SEQ ID NO: 3; c) optionally substituting one or more further amino acids as defined in b); d) preparing the variant resulting from steps a)-c); e) determining the specific activity at least one pH and/or the pH optimum of the variant; and f) selecting a variant having an increased specific activity at least one pH in comparison to the parent asparaginase polypeptide and/or an increased pH optimum in comparison to the parent asparaginase polypeptide, thereby to produce an asparaginase polypeptide variant.

15. A method according to claim 14, wherein the parent asparaginase polypeptide has the sequence set out in SEQ ID NO: 3.

16. A method according to claim 14 wherein in step b) at least one amino acid residue corresponding to any of positions 53, 64, 66, 73, 74, 88, 90, 91, 111, 161, 211, 228, 262, 267, 295, 303, 310, 314, 317, 321, 324, 330, 332, or 333 is substituted; said positions being defined with reference to SEQ ID NO: 3, and wherein the parent polypeptide has at least 90% homology with SEQ ID NO: 3.

17. A method according to claim 16 wherein in step b) the substituted amino acid residue corresponds to one or more of Tyr at position 53; Pro at position 64; Pro at position 66; Lys at position 73; Ala at position 74; Tyr or Pro at position 88; Val at position 90; Glu at position 91; Gly at position 111; Leu at position 161; Ser at position 211; His at position 228; Cys or His at position 262; Tyr at position 267; Ser at position 295; Ser at position 303; Val at position 310; Asp at position 314; Ile at position 317; Thr at position 321; Gly at position 324; Ser at position 330; Ala at position 332; or Glu at position 333; said positions being defined with reference to SEQ ID NO: 3.

18. A composition comprising the variant according to claim 1.

19. A process for the production of a food product involving at least one heating step, comprising adding one or more asparaginase enzymes according to claim 1 to an intermediate form of said food product in said production process, whereby the enzyme is added prior to said heating step in an amount that is effective in reducing the level of asparaginase that is present in said intermediate form of said food product.

Summary for Patent:   Try a Free Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07106612Apr 20, 2007
07106620Apr 20, 2007
07106660Apr 20, 2007
07106662Apr 20, 2007
07106664Apr 20, 2007

Details for Patent 9,127,266

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Try a Free Trial DSM IP ASSETS B.V. (Heerlen, NL) 2027-04-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 9,127,266

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2008128974 Oct 30, 2008
World Intellectual Property Organization (WIPO) 2008128975 Oct 30, 2008
United States of America 2010136169 Jun 03, 2010
United States of America 2010183765 Jul 22, 2010
United States of America 2012045549 Feb 23, 2012
United States of America 2013023029 Jan 24, 2013
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
UBS
Fish and Richardson
Baxter
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.